Home » Topics » Science » Drug design, drug delivery and technologies

Drug design, drug delivery and technologies
RSS

Drug development agreement reached by Megabios and Pfizer

June 21, 1996

HemaSure/American Red Cross Biomedical Services alliance

June 14, 1996

Exelixis acquires rights to P Element technology

June 14, 1996

Bayer/CV Therapeutics antiinflammatory drug agreement

June 14, 1996

Bristol-Myers Squibb/Garvan Institute of Medical Research collaboration

June 14, 1996

Ingenex granted phase II SBIR grant

June 14, 1996

Neoprobe and Dow enter licensing agreement

June 7, 1996

Research agreement: TCPI and the University of Kansas

June 7, 1996

CompuMed and the University of Massachusetts Medical Center enter agreement

June 7, 1996

Patient enrollment for Alkermes' RMP-7 trials complete

June 7, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...